Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.

@article{Scherlinger2017SwitchingFO,
  title={Switching from originator infliximab to biosimilar CT-P13 in real-life: The weight of patient acceptance.},
  author={Marc Scherlinger and Vincent Germain and C{\'e}line Labadie and Thomas Barnetche and M E Truchetet and Bernard Bannwarth and Nadia Mehsen-C{\^e}tre and Christophe Richez and Thierry Schaeverbeke},
  journal={Joint, bone, spine : revue du rhumatisme},
  year={2017}
}
OBJECTIVE To explore acceptance and retention rate of biosimilar CT-P13 after switching from originator infliximab (OI) in patients with various rheumatic diseases. METHODS Patients with stable rheumatoid arthritis (RA), ankylosing spondylitis (AS) or psoriatic arthritis (PsA) under OI were proposed to switch to CT-P13 at the same regimen. A prospective… CONTINUE READING